| Literature DB >> 31726755 |
Zhong Peng1,2, Zizhe Hu1,2, Zugang Li1,2, Xiaosong Li1,2, Chaoying Jia1,2, Xiaoxue Zhang1,2, Bin Wu1,2, Huanchun Chen1,2, And Xiangru Wang1,2.
Abstract
Enterobacteriaceae having chromosomally-encoded mcr-1 is rarely reported. In this study, we recovered a chromosomal mcr-1 carrying Escherichia coli, designated HeN100, from the feces of a diarrheal pig in China. Antimicrobial susceptibility testing showed that HeN100 was resistant to three aminoglycosides, twelve β-lactams including three carbapenems, one phenicol, two tetracyclines, two fluoroquinolones, nitrofurantoin, and colistin tested. Oxford Nanopore MinION sequencing revealed that the complete genomes of the multidrug resistant (MDR) HeN100 consisted of a single circular chromosome and five circular plasmids. Bioinformatical analysis determined HeN100 as ST695 and it contained many acquired resistance genes responsible for its MDR phenotypes, including colistin resistance mcr-1 and the carbapenem resistance blaNDM-1, and most of these genes were located on plasmids. However, the mcr-1 was found on the chromosome, and it was located between an IS30-like element ISApl1 and a PAP2-like encoding gene. These three genes consisted of an "ISApl1-mcr-1-orf" segment and inserted in high AT-rich regions. Finally, we found the blaNDM-1 was carried on an IncFII type conjugative plasmid. The conjugation frequency of this plasmid was 7.61 ± 2.11 × 10-5 per recipient, and its conjugation conferred resistance to carbapenems and other β-lactams, as well as aminoglycosides. The spread of this mcr-1/blaNDM-1-carrying E. coli ST695 represents a great concern of public health.Entities:
Keywords: Escherichia coli; Oxford Nanopore MinION sequencing; ST695; antibiotic resistance; chromosomally-encoded mcr-1; plasmid conjugation; plasmid-carrying blaNDM-1
Year: 2019 PMID: 31726755 PMCID: PMC6920969 DOI: 10.3390/microorganisms7110558
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Resistance profile of E. coli HeN100.
| Antibiotics | MIC Values (μg/mL) and Interpretation | Interpretation Criteria (μg/mL) | |||
|---|---|---|---|---|---|
| HeN100 | ATCC25922 | S | I | R | |
| CL ǂ | >4 (R) | ≤1 (S) | ≤2 | - | >2 |
| AMK § | >32 (R) | ≤8 (S) | ≤16 | 32 | ≥64 |
| GEN § | >8 (R) | ≤2 (S) | ≤4 | 8 | ≥16 |
| TOB § | >8 (R) | ≤2 (S) | ≤4 | 8 | ≥16 |
| IPM § | >8 (R) | ≤0.25 (S) | ≤1 | 2 | ≥4 |
| MRP § | >8 (R) | ≤0.13 (S) | ≤1 | 2 | ≥4 |
| ETP § | >2 (R) | ≤0.25 (S) | ≤0.5 | 1 | ≥2 |
| CFZ § | >16 (R) | ≤2 (S) | ≤16 | - | ≥32 |
| CFX § | >16 (R) | ≤4 (S) | ≤8 | 16 | ≥32 |
| FOX § | >16 (R) | ≤4 (S) | ≤8 | 16 | ≥32 |
| CAZ § | >32 (R) | ≤1 (S) | ≤4 | 8 | ≥16 |
| CRO § | >32 (R) | ≤1 (S) | ≤1 | 2 | ≥4 |
| CPM § | >16 (R) | ≤1 (S) | ≤2 | - | ≥16 |
| AMC § | >32/16 (R) | ≤8/4 (S) | ≤8/4 | 16/8 | ≥32/16 |
| AMS § | >16/8 (R) | ≤4/2 (S) | ≤8/4 | 16/8 | ≥32/16 |
| PTZ § | >64/4 (R) | ≤4/4 (S) | ≤16/4 | 32/4–64/4 | ≥128/4 |
| CHL § | >16 (R) | ≤4 (S) | ≤8 | 16 | ≥32 |
| MXF ǂ | >2 (R) | ≤0.5 (S) | ≤0.25 | - | >0.25 |
| CIP § | 2 (R) | ≤0.5 (S) | ≤1 | 2 | ≥4 |
| LVX § | 2 (S) | ≤1 (S) | ≤2 | 4 | ≥8 |
| NOR § | 4 (S) | ≤2 (S) | ≤4 | 8 | ≥16 |
| TET § | >8 (R) | ≤2 (S) | ≤4 | 8 | ≥16 |
| MIN § | 16 (R) | ≤1 (S) | ≤4 | 8 | ≥16 |
| TGC ǂ | 2 | ≤1 (S) | ≤1 | - | >2 |
| NIT § | >64 (R) | ≤16 (S) | ≤32 | 64 | ≥128 |
| FOS § | ≤16 (S) | ≤16 (S) | ≤64 | 128 | ≥256 |
| SXT | ≤1/19 (S) | ≤1/19 (S) | ≤2/38 | - | ≥4/76 |
| AZM § | ≤2 (S) | ≤2 (S) | ≤4 | 8 | ≥16 |
§ Interpretation criteria and breakpoints referred to CLSI M100 ed28-2018. ǂ Interpretation criteria and breakpoints referred to EUCAST Clinical breakpoints—bacteria (v 8.1). R: Resistant; S: susceptible; I: intermediately resistant. CL: colistin; AMK: amikacin; GEN: gentamicin; TOB: tobramycin; IPM: imipenem; MRP: meropenem; ETP: ertapenem; CFZ: cefazolin; CFX: cefuroxime; FOX: cefoxitin; CAZ: ceftazidime; CRO: ceftriaxone; CPM: cefepime; AMC: amoxicillin/clavulanate; AMS: ampicillin/sulbactam; PTZ: piperacillin/tazobactam; CHL: chloramphenicol; MXF: moxifloxacin; CIP: ciprofloxacin; LVX: levofloxacin; NOR: norfloxacin; TET: tetracycline; MIN: minocycline; TGC: tigecycline; NIT: nitrofurantoin; FOS: fosfomycin; SXT: trimethoprim/sulfamethoxazole; AZM: aztreonam.
Figure 1Phylogenetic analysis of E. coli ST695 strains and E. coli strains harboring a chromosomal mcr-1 gene. The tree with the highest log likelihood (–14462.49) is shown. The evolutionary history was inferred by using the Maximum Likelihood method and Tamura-Nei model. The percentage of trees in which the associated taxa clustered together is shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. This analysis involved 19 nucleotide sequences. There were a total of 9015 positions in the final dataset. Evolutionary analyses were conducted in MEGA X. The circles denote bootstrap values within range of 0.015-0.838.
Figure 2Heatmap showing the presence of antibiotic resistance genes in E. coli ST695. Boxes in pink represent a resistance gene is present in the genome analyzed while boxes in light blue represent a resistance gene is not present in the genome analyzed.
Figure 3Circle maps of the resistance genes carrying plasmids harbored by the multidrug resistance E. coli HeN100. (A) Circle maps of the resistance plasmid pHeN100-01 carried by HeN100; (B) circle maps of the resistance plasmid pHeN100-04 carried by HeN100. The maps were generated by dnaplotter. Circles from inside to outside showing GC skew (circle 1), GC plot (circle 2), DNA sequence (circle 3), functional genes (circle 4). Resistance genes are displayed as arrows in red while arrows in blue represent putative insertion elements.
Figure 4Genetic structure of the chromosomal mcr-1. (A) Genome comparisons of seven E. coli chromosomes. The chromosomal genome sequences of three E. coli strains (HeN100, SZH3951, EC590, S51) harboring the chromosomal mcr-1 and three ST695 strains that do not carry mcr-1. Sequence comparison was performed using BRIG package. DNA identities between different sequences are shown in different colors. (B) Genetic structures of chromosomal mcr-1 and their comparative analysis among different E. coli strains. Sequence comparison was performed using EasyFig package (version 2.2.2). Color code stands for BLASTn identity of those regions between strains. Arrows in orange, purple, and green represent ISApl1, mcr-1, and the linked open reading frame, respectively. (C) The insertion sites of the mcr-1 segments in E. coli chromosomes. DNA sequences of 32 bp around the insertion sites (16 bp from both parts) in the four complete genomes were compared and analyzed using WebLogo.
Figure 5Comparative analysis of plasmids pHeN100-04 and pHNEC55. Sequence comparison was performed using EasyFig package (version 2.2.2). Color code stands for BLASTn identity of those regions between strains. Arrows represent open reading frames encoded by each of the plasmid sequences. Antibiotic resistance genes in each of the plasmid sequences were shown in orange arrows while insertion sequence (IS) elements were shown in purple arrows.
Phenotypical characteristics of the transconjugants selected by rifampin plus imipenem.
| Antibiotics Tested | Minimum Inhibitory Concentration (μg/mL) | |
|---|---|---|
| Transconjugants | ||
| Amikacin | >32 (R) | ≤8 (S) |
| Gentamicin | >8 (R) | ≤2 (S) |
| Tobramycin | >8 (R) | ≤2 (S) |
| Ertapenem | >2 (R) | ≤0.25 (S) |
| Imipenem | >8 (R) | 0.5 (S) |
| Meropenem | >8 (R) | ≤0.13 (S) |
| Cefazolin | >16 (R) | 4 (S) |
| Cefuroxime | >16 (R) | 16 (R) |
| Cefoxitin | >16 (R) | 8 (S) |
| Ceftazidime | >32 (R) | ≤1 (S) |
| Ceftriaxone | >32 (R) | ≤1 (S) |
| Cefepime | 16 (R) | ≤1 (S) |
| Amoxicillin/clavulanate | >32/16 (R) | ≤8/4 (S) |
| Ampicillin/sulbactam | >16/8 (R) | 8/4 (S) |
| Piperacillin/tazobactam | >64/4 (R) | ≤4/4 (S) |
| Colistin | ≤1 (S) | ≤1 (S) |
| Chloramphenicol | ≤4 (S) | ≤4 (S) |
| Moxifloxacin | ≤0.5 (S) | ≤0.5 (S) |
| Ciprofloxacin | ≤0.5 (S) | ≤0.5 (S) |
| Levofloxacin | ≤1 (S) | ≤1 (S) |
| Norfloxacin | ≤2 (S) | ≤2 (S) |
| Tetracycline | ≤2 (S) | ≤2 (S) |
| Minocycline | ≤1 (S) | ≤1 (S) |
| Trimethoprim/sulfamethoxazole | ≤1/19 (S) | ≤1/19 (S) |
| Aztreonam | ≤2 (S) | ≤2 (S) |
| Fosfomycin | ≤16 (S) | ≤16 (S) |
| Nitrofurantoin | ≤16 (S) | ≤16 (S) |
| Tigecycline | ≤1 (S) | ≤1 (S) |
R: Resistant; S: susceptible; I: intermediately resistant.